References
1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal
origin of SARS-CoV-2. Nat Med . 2020;26(4):450-452.
2. Mulangu S, Dodd LE, Davey Jr RT, et al. A randomized, controlled
trial of Ebola virus disease therapeutics. N Engl J Med .
2019;381(24):2293-2303.
3. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral
GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci
Transl Med . 2017;9(396).
4. Pruijssers AJ, George AS, Schäfer A, et al. Remdesivir potently
inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing
the SARS-CoV-2 RNA polymerase in mice. 2020.
5. Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the
anti-coronavirus effect of remdesivir. Drug Discov Ther .
2020;14(2):73-76. doi:10.5582/ddt.2020.01015
6. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment
of Covid-19—preliminary report. N Engl J Med . 2020.
7. Dorward J, Gbinigie K. Lopinavir/ritonavir: A rapid review of
effectiveness in COVID-19. 2020.
8. Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of
interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment
of patients admitted to hospital with COVID-19: an open-label,
randomised, phase 2 trial. Lancet . 2020;395(10238):1695-1704.
doi:10.1016/s0140-6736(20)31042-4
9. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir
for COVID-19: an open-label control study. Engineering . 2020.
10. Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to
lopinavir/ritonavir in treating COVID-19. J Infect . 2020.
11. Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for
COVID-19: a randomized clinical trial. MedRxiv . 2020.
12. Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, McDonald DR.
Immunoglobulins in the treatment of COVID-19 infection: Proceed with
caution! Clin Immunol . 2020:108459.
13. Syal K. COVID‐19: herd immunity and convalescent plasma transfer
therapy. J Med Virol . 2020.
14. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel
treatment approach to the novel coronavirus: an argument for the use of
therapeutic plasma exchange for fulminant COVID-19. 2020.
15. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma
therapy in severe COVID-19 patients. Proc Natl Acad Sci .
2020;117(17):9490-9496.
16. Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M,
Ramachandran A. Convalescent plasma transfusion for the treatment of
COVID‐19: Systematic review. J Med Virol . 2020.
17. Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of
antibodies to SARS-associated coronavirus after recovery. N Engl J
Med . 2007;357(11):1162-1163.
18. Kumar GV, Jeyanthi V, Ramakrishnan S. A short review on antibody
therapy for COVID-19. New Microbes New Infect . 2020:100682.
19. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19
patients with tocilizumab. Proc Natl Acad Sci .
2020;117(20):10970-10975.
20. Sallard E, Lescure F-X, Yazdanpanah Y, et al. Type 1 interferons as
a potential treatment against COVID-19. Antiviral Res .
2020:104791.
21. Huang X, Zhou M-Y, Cheng Y, et al. Opportunities and challenges of
traditional Chinese medicine going abroad for COVID-19 treatment.Am J Emerg Med . 2020;(January). doi:10.1016/j.ajem.2020.06.008
22. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine
in the treatment of patients infected with 2019-new coronavirus
(SARS-CoV-2): a review and perspective. Int J Biol Sci .
2020;16(10):1708.
23. Gao D, Niu M, Wei S, et al. Identification of a Pharmacological
Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component
TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1)
Infection. Front Pharmacol . 2020;11:746.
24. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation
of patients with SARS-CoV-2 infection. Clin Chem Lab Med .
2020;1(ahead-of-print).
25. Yin S, Huang M, Li D, Tang N. Difference of coagulation features
between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J
Thromb Thrombolysis . 2020:1.
26. Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the
risk of thromboembolism in COVID-19 patients. J Vasc Surg . 2020.
27. Cox MJ, Loman N, Bogaert D, O’grady J. Co-infections: potentially
lethal and unexplored in COVID-19. The Lancet Microbe .
2020;1(1):e11.
28. Sodhi M, Etminan M. Therapeutic Potential for Tetracyclines in the
Treatment of COVID‐19. Pharmacother J Hum Pharmacol Drug Ther .
2020;40(5):487-488.
29. Conforti C, Giuffrida R, Zalaudek I, Di Meo N. Doxycycline, a widely
used antibiotic in dermatology with a possible anti‐inflammatory action
against IL‐6 in COVID‐19 outbreak. Dermatol Ther . 2020.
30. Huang M, Li M, Xiao F, et al. Preliminary evidence from a
multicenter prospective observational study of the safety and efficacy
of chloroquine for the treatment of COVID-19. MedRxiv . 2020.
31. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and
azithromycin as a treatment of COVID-19: results of an open-label
non-randomized clinical trial. Int J Antimicrob Agents .
2020:105949.
32. Borba M, de Almeida Val F, Sampaio VS, et al. Chloroquine
diphosphate in two different dosages as adjunctive therapy of
hospitalized patients with severe respiratory syndrome in the context of
coronavirus (SARS-CoV-2) infection: Preliminary safety results of a
randomized, double-blinded, phase IIb cl. MedRxiv . 2020.
33. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with
COVID-19 treated with hydroxychloroquine and azithromycin. Nat
Med . 2020:1-2.
34. Juurlink DN. Safety considerations with chloroquine,
hydroxychloroquine and azithromycin in the management of SARS-CoV-2
infection. CMAJ . 2020;192(17):E450-E453.
35. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with
hydroxychloroquine or azithromycin with in-hospital mortality in
patients with COVID-19 in New York state. Jama . 2020.
36. Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in
Hospitalized Patients with COVID-19: Preliminary Report. MedRxiv .
2020:2020.06.22.20137273. doi:10.1101/2020.06.22.20137273
37. Cheng RZ. Can early and high intravenous dose of vitamin C prevent
and treat coronavirus disease 2019 (COVID-19)? Med Drug Discov .
2020;5:100028.
38. Carr AC. A new clinical trial to test high-dose vitamin C in
patients with COVID-19. Crit Care . 2020;24(1):1-2.
39. Liu Y, Pang Y, Hu Z, et al. Thymosin alpha 1 (Tα1) reduces the
mortality of severe COVID-19 by restoration of lymphocytopenia and
reversion of exhausted T cells. Clin Infect Dis . 2020.
40. Leslie M. T cells found in coronavirus patients ‘bode well’ for
long-term immunity. Science (80- ) . 2020;368(6493):809-810.
doi:10.1126/science.368.6493.809
41. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential
treatment for 2019-nCoV acute respiratory disease. Lancet (London,
England) . 2020;395(10223):e30.
42. Chatterjee S. SGLT-2 inhibitors for COVID-19—A miracle waiting to
happen or just another beat around the bush? Prim Care Diabetes .
2020.
43. Amanat F, Krammer F. SARS-CoV-2 vaccines: status report.Immunity . 2020.
44. Mullard A. COVID-19 vaccine development pipeline gears up.Lancet . 2020;395(10239):1751-1752.
45. Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for
COVID-19: the current state of play. Paediatr Respir Rev . 2020.
46. McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2
lipid nanoparticle vaccine induces equivalent preclinical antibody
titers and viral neutralization to recovered COVID-19 patients.bioRxiv . 2020.
47. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19
vaccines at pandemic speed. N Engl J Med . 2020;382(21):1969-1973.